Press Release 23 June 2010 
B1 Medical Ltd Signs Collaboration Agreement with IPSO Ventures PLC
B1 Medical Limited (“B1”) is pleased to announce that it has signed an agreement with IPSO Ventures plc (“IPSO”) the creator of commercial value from technology, to collaborate on the development of a device for diagnosing Acute Compartment Syndrome (“ACS”).
B1 has developed a monitor (“the B1 Monitor”), based on the measurement of tissue pH, to provide an early indication of the likely onset of ACS. This is a condition which occurs mainly in trauma/crush victims and patients who have undergone surgery. ACS is caused when swelling occurs within a closed compartment (e.g. in the arm or leg) and as swelling continues nerves and arteries can be crushed and muscle can die. Early diagnosis of ACS is paramount, as without treatment it can lead to paralysis, loss of a limb or even death. There are currently no robust diagnostic tests for acute intramuscular ischaemic vascular conditions.
The novel B1 technology allows early diagnosis of ACS and initial clinical studies indicate that it has better diagnostic capability than the current gold standard, which uses pressure measurement.
IPSO has developed novel micro-electrodes for the accurate measurement of pH in extremely small volumes of liquid. One embodiment being developed is a micro-electrode for insertion into tissue for the continuous measurement of pH. This will form the basis of a disposable micro-probe, for use in conjunction with the B1 Monitor, for monitoring likely onset of ACS in trauma patients.
Mark Wickham, CEO of B1, said: “I am very pleased that our two companies have come together to develop a product for which there is a real clinical need. The Monitor will aid the early diagnosis and treatment of ACS and the market potential for a product that accurately diagnoses this serious condition is significant.”
Nick Rodgers, CEO of IPSO, added: “We are very excited to work with B1 on the development of such a novel product. This is yet another example of how we develop technologies which are commercially relevant. By bringing together know-how and IP from various sources, we are able to address serious commercial needs and add significant value for shareholders.”
B1 Medical Limited: Tel 01224 715900
Mark Wickham, CEO mark.wickham@b1medical.com
Hans Steuten, General Manager hans.steuten@b1medical.com
IPSO Ventures plc: Tel: 020 7921 2990
Simon Hunt, Chairman simon@ipsoventures.com
Nick Rogers, Chief Executive nick@ipsoventures.com
Press Release 19 May 2010
B1 Medical and Invibio® Biomaterial Solutions Collaborate on Development of Innovative New Orthopaedic Products
B1 Medical, the Aberdeen-based company dedicated to the development and commercialisation of innovative medical devices in the field of orthopaedics, has partnered together with Invibio® Biomaterial Solutions, a worldwide leading provider of high-performance implantable biomaterials to the surgical and medical device markets, to provide scientific support on B1 Medical's development of a novel PEEK-OPTIMA® polymer suture anchor and a pioneering new PEEK-OPTIMA® based replacement small joint.
B1 has a novel suture anchor system designed to give strong tissue fixation and ease to new surgeons. This patented design will be used as the basis of the new anchor manufactured from PEEK-OPTIMA®.
PEEK-OPTIMA® is also the base material chosen for B1's innovative new replacement small joint that addresses many of the drawbacks of existing designs and will open up a significant new untapped market for small joint replacement.
Invibio Biomaterial Solutions provides comprehensive resource and technical expertise to speed up time to market for new medical device designs. Their market leading position in advanced biomaterials, combined with powerful value added services allows new medical devices to realise accelerated market success.
Speaking about the agreement, Mark Wickham CEO of B1 Medical said: "I am delighted that our two companies have come together to collaborate on these exciting new products. B1 Medical has a first look and option agreement with the prestigious institutions of NHS Grampian, the University of Aberdeen and the Robert Gordon University on IP in the field of Orthopaedics. The novel suture anchor system and small joint are examples of a pipeline of orthopaedic products that B1 has in development.
Dr John Devine, Strategic Development Director of Invibio Biomaterial Solutions added "Invibio is dedicated to encouraging innovation in the medical device industry by offering technical advice as we have with B1, for example on component prototyping development, best practice processing knowledge and material characteristics. We are very pleased to be working with B1 Medical and believe that this partnership of novel device development will provide a compelling offering of new orthopaedic devices that bring real benefits to patients.
About Invibio: Invibio® is a global leader providing high performance biomaterials, advanced technical research and consultative solutions to medical device manufacturers across a wide range of markets. The company provides medical device manufacturers with PEEK-OPTIMA® polymer and compounds, Motis™ polymer, ENDOLIGN® composite and PEEK-CLASSIX™ polymer for the development of long and short-term implantable medical devices.
For more information, please contact Invibio at: +866 468 4246 or
+484 342 6004 (US), (0) 1253 898000 (UK), +852 2366 4448 (Asia Pacific) or online at www.invibio.com.
Press Release 28 March 2010
B1 Medical and Giltec Collaborate on Development of Innovative Biodegradable Suture Anchor
B1 Medical, the innovative Aberdeen-based company dedicated to the development and commercialisation of medical devices in the field of orthopaedics, and Giltech, a world leader in the field of controlled delivery and biodegradable technologies have signed an agreement to collaborate on the development of a pioneering suture anchor.
B1 has a pioneering suture anchor system that enables easy single step insertion, which it plans to develop as a complementary product to its existing portfolio. The combination of this original design and Giltech’s biodegradable glass would provide a much-sought after product in the orthopaedic world – a suture anchor that degrades in the body in a highly controlled fashion.
Giltech has been working with biodegradable phosphate glasses for over twenty years and has an unparalleled knowledge and skill base around this versatile material. Its CorGlaes™ Pure is uniquely formulated for each bespoke application to ensure the appropriate dissolution profile is achieved.
The collaboration will be the first for the two companies but demonstrates the benefits of combining the skills of two different but equally innovative companies within the Scottish Life Sciences arena.
Speaking about the deal, Mark Wickham CEO of B1 Medical said:
“I am delighted that our two companies have come together to collaborate on the development of this exciting new product. B1 Medical has an exclusive first look and option agreement with the prestigious Institutions of NHS Grampian, the University of Aberdeen and the Robert Gordon University on intellectual property generated in the field of orthopaedics. The novel suture anchor system is an example of the several innovative new orthopaedic products that B1 Medical has in development.”
Gillian Watson, Managing Director of Giltech added:
“Our biodegradable glass has been used for many years in medical devices and woundcare products, primarily as a system for the controlled delivery of certain metal ions. We have explored a number of opportunities to enter the orthopaedics market and consider the arrangement with B1 to be the most compelling. Its novel suture anchor design is in itself a potential market leader. We’re very much looking forward to this collaboration and the positive results it will generate.”
For further information please visit www.b1medical.com and ww.giltech.biz
Press Release 26 August 2009
Appointment of Chief Executive Officer
Dr Mark Wickham has joined the board of B1 Medical Ltd as CEO
Mark has held a number of senior roles in the medical device industry, most recently as Operations Director at leading Orthopaedic company Smith & Nephew's Research Centre in York.
He said on his appointment 'I am delighted to join the Board of B1 Medical as Chief Executive Officer. I come from an orthopaedics background and have a real passion for seeing innovative new orthopaedic products developed and taken to market. B1 Medical's leading edge products and pipeline agreement with prestigious Institutions bode well for the future and the Company's continuing development.
Press Release 26 August 2009
New Investment
B1 Medical Limited is pleased to announce that it has completed a second round financing of £1.1m.
Investors in the round included Barwell plc and RGU Ventures Investment Fund, the management team and existing shareholders Scottish Enterprise Co-investment Fund, Robert Gordon University, the University of Aberdeen, Scottish Health Innovations Limited and Sigma Technology Management Limited.
Dr Mark Wickham said, 'The high growth orthopaedics sector provides an exciting opportunity for leading-edge new products that address real clinical needs. This investment provides a fantastic opportunity for B1 Medical to further develop its portfolio of innovative new products and invest in expanding the company’s marketing and sales resources.'
Press Release 12 February 2007
Aberdeen-based life sciences company B1 Medical scooped the Most Promising New Life Sciences Company in Scotland at the SE Life Sciences Awards 2007 for its revolutionary orthopaedic inventions, set to aid sufferers of illnesses such as rheumatoid arthritis. The company was founded in July 2006 with £1.3m investment from Sigma Capital Group PLC (AIM: SGM), the specialist asset management and advisory group, and Scottish Enterprise CIF. B1 Medical is a spin-out from the University of Aberdeen, the Robert Gordon University and NHS Grampian.
Press Release 17 July 2006
Sigma Capital Group PLC today announced a £1.3 million investment in B1 Medical Limited (“B1 Medical”). Sigma has been working closely with the three founding institutions: the University of Aberdeen, the Robert Gordon University, and NHS Grampian, represented by Scottish Health Innovations Ltd, (“the Institutions”) since the creation of B1 Medical which will focus on the commercialisation of technology in the field of medical devices for orthopaedics.
